Official Title
Clonal Architecture of ASXL1-mutated Myelofibrosis
Brief Title
Clonal Architecture of ASXL1-mutated Myelofibrosis
Protocol ID
NCT05710211
Lead Sponsor
University Hospital, Angers
Brief Summary
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and
secondary myelofibrosis and its impact on prognosis
Detailed Description
The clonal architecture of myelofibrosis patients is still little described. Inconsistent
results in terms of the prognostic value of some mutations are observed in the
literature, in particular concerning ASXL1 mutations. We assume that a better
understanding of the clonal architecture of ASXL1-mutated myelofibrosis could help
refining the prognostic impact of ASXL1 mutations.
This study aims to evaluate a multicenter cohort of 50 patients. Blood of patients will
be collected within 18 months of diagnosis. After 4 years of follow-up of the patient as
part of his usual care, data on survival and leukemic transformation will be collected.
Study Period
-
Enrollment Count
50 participants
Eligibility Criteria
Inclusion Criteria:
- Adults (age ≥18 years),
- Affiliated to the national social security system,
- ASXL1 mutated primary or secondary myelofibrosis,
- Signed the consent to participate in the study,
- Included, or consenting to be included, in the national clinical-biological database
of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Exclusion Criteria:
- Patient with another active hematological disease or cancer at the time of
diagnosis,
- Person subject to legal protection scheme or incapable of giving consent.
Filters
Myelofibrosis
NA
RECRUITING
ADULT
OLDER_ADULT